Spots Global Cancer Trial Database for endocrine system diseases
Every month we try and update this database with for endocrine system diseases cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca | NCT01555489 | Stage IV Pancre... | Ascorbic Acid | 18 Years - | Thomas Jefferson University | |
| Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy | NCT05022667 | Thyroid Neoplas... Thyroid Disease... Hypoparathyroid... Endocrine Syste... Endocrine Gland... Neoplasms by Si... Neoplasms Head and Neck N... Parathyroid Dis... | PTeye | 18 Years - | University of Michigan | |
| Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers | NCT01523678 | Ovarian Cancer Endometrial Can... Uterine Cervica... | Filgrastim Paclitaxel Carboplatin | 18 Years - | Belgian Gynaecological Oncology Group | |
| One Week Comparison Study of PTH and PTHrP Infusions | NCT01333267 | Osteoporosis Hypercalcemia o... Hyperparathyroi... Bone Diseases, ... | Parathyroid Hor... parathyroid hor... PTH (1-34) and ... | 24 Years - 35 Years | University of Pittsburgh | |
| A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma | NCT02993731 | Carcinoma, Panc... | Napabucasin Nab-paclitaxel Gemcitabine | 18 Years - | Sumitomo Pharma America, Inc. | |
| Dissecting the IMpact of 11-OXygenated and Classic Androgens on Skeletal Muscle Insulin Sensitivity (DIMOXIS) | NCT05263557 | Polycystic Ovar... Insulin Resista... Androgen; Hyper... Endocrine Syste... | Dehydroepiandro... 11-ketoandroste... | 18 Years - 40 Years | Royal College of Surgeons, Ireland | |
| Phenotype and Epidemiology of the Polycystic Ovary Syndrome (PCOS) in Colombia (PEP - Colombia) Study. | NCT05926115 | Polycystic Ovar... Hyperandrogenis... Endocrine Syste... | Diagnostic Ultr... Venous puncture | 18 Years - 45 Years | Instituto de fertilidad humana, InSer | |
| Research on the Application and Mechanism of New Biological Probes in Biomedicine | NCT04977739 | Tumors Cardiovascular ... Respiratory Sys... Digestive Syste... Endocrine Syste... Metabolic Disea... Immune System D... Urinary System ... Nervous System ... Blood Diseases Infectious Dise... | No intervention | 18 Years - 70 Years | Nanfang Hospital, Southern Medical University | |
| One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study | NCT00580788 | Osteoporosis Humoral Hyperca... Hyperparathyroi... | PTHrP (1-36) | 24 Years - 35 Years | University of Pittsburgh | |
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | NCT03157128 | Non-Small Cell ... Medullary Thyro... Colon Cancer Any Solid Tumor | LOXO-292 | 12 Years - | Eli Lilly and Company | |
| Phenotype and Epidemiology of the Polycystic Ovary Syndrome (PCOS) in Colombia (PEP - Colombia) Study. | NCT05926115 | Polycystic Ovar... Hyperandrogenis... Endocrine Syste... | Diagnostic Ultr... Venous puncture | 18 Years - 45 Years | Instituto de fertilidad humana, InSer | |
| Research on the Application and Mechanism of New Biological Probes in Biomedicine | NCT04977739 | Tumors Cardiovascular ... Respiratory Sys... Digestive Syste... Endocrine Syste... Metabolic Disea... Immune System D... Urinary System ... Nervous System ... Blood Diseases Infectious Dise... | No intervention | 18 Years - 70 Years | Nanfang Hospital, Southern Medical University | |
| A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer | NCT03535727 | Adenocarcinoma Pancreatic Neop... Neoplasm, Gland... Neoplasms Neoplasms Pancr... Digestive Syste... Endocrine Gland... Digestive Syste... Pancreatic Dise... Endocrine Syste... | Nab-paclitaxel Gemcitabine Capecitabine Cisplatin Irinotecan Nab-paclitaxel Gemcitabine Capecitabine Cisplatin Irinotecan | 18 Years - 76 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Research on the Application and Mechanism of New Biological Probes in Biomedicine | NCT04977739 | Tumors Cardiovascular ... Respiratory Sys... Digestive Syste... Endocrine Syste... Metabolic Disea... Immune System D... Urinary System ... Nervous System ... Blood Diseases Infectious Dise... | No intervention | 18 Years - 70 Years | Nanfang Hospital, Southern Medical University | |
| A BHI to Increase Hope Level and Stress Level of Parents With a CMC | NCT05269693 | Child With Canc... Muscular Atroph... Child With Cere... Endocrine Syste... | Brief Hope Inte... | - | The Hong Kong Polytechnic University | |
| Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer | NCT03562897 | Carcinoma Ovarian Neoplas... Endocrine Gland... Urogenital Neop... Ovarian Disease... Adnexal Disease... Genital Disease... Female Urogenit... Female Urogenit... Endocrine Syste... Gonadal Disorde... Genital Neoplas... Neoplasms, Glan... | Ocoxin-Viusid | 18 Years - | Catalysis SL | |
| Prospective Validation and Comparison of Different Ultrasound Methods for Discrimination Between Benign and Malignant Ovarian/Tubal Masses Prior to Surgery | NCT02847832 | Patients With A... | Standardized tr... | - | KU Leuven | |
| Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction | NCT03492242 | Arthritis Cancer Cardiac Disease Endocrine Syste... Autoimmune Dise... Ophthalmopathy Myositis Neuropathy | Immune checkpoi... | 18 Years - | Groupe Hospitalier Pitie-Salpetriere | |
| Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer | NCT02385617 | Esophageal Neop... Stomach Neoplas... Weight Loss Malnutrition | Octreotide Placebo | 18 Years - 100 Years | St. James's Hospital, Ireland | |
| Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma | NCT03717298 | Adenocarcinoma ... Pancreatic Canc... Advanced Cancer Digestive Syste... Pancreatic Neop... Endocrine Gland... Digestive Syste... Endocrine Syste... Pancreatic Dise... | Ocoxin-Viusid® | 18 Years - | Catalysis SL | |
| Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca | NCT01555489 | Stage IV Pancre... | Ascorbic Acid | 18 Years - | Thomas Jefferson University | |
| One Week Comparison Study of PTH and PTHrP Infusions | NCT01333267 | Osteoporosis Hypercalcemia o... Hyperparathyroi... Bone Diseases, ... | Parathyroid Hor... parathyroid hor... PTH (1-34) and ... | 24 Years - 35 Years | University of Pittsburgh | |
| A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) | NCT00749502 | Solid Tumors Chronic Lymphoc... T-cell-prolymph... | MK-4827 | 18 Years - | Tesaro, Inc. | |
| Dietary Patterns and Health Outcomes (Cardiovascular, Metabolic, Endocrine, Neurological, Skeletal Muscular, Cancer) | NCT03328546 | Cardiovascular ... Cerebrovascular... Metabolic Disea... Neoplasms Endocrine Syste... Neurologic Symp... Skeletal Anomal... Diabetes Mellit... Pregnancy Compl... | Dietary intake | 24 Years - 44 Years | Harvard School of Public Health (HSPH) | |
| Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer | NCT03562897 | Carcinoma Ovarian Neoplas... Endocrine Gland... Urogenital Neop... Ovarian Disease... Adnexal Disease... Genital Disease... Female Urogenit... Female Urogenit... Endocrine Syste... Gonadal Disorde... Genital Neoplas... Neoplasms, Glan... | Ocoxin-Viusid | 18 Years - | Catalysis SL | |
| Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma | NCT03717298 | Adenocarcinoma ... Pancreatic Canc... Advanced Cancer Digestive Syste... Pancreatic Neop... Endocrine Gland... Digestive Syste... Endocrine Syste... Pancreatic Dise... | Ocoxin-Viusid® | 18 Years - | Catalysis SL | |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | NCT03899792 | Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar... | LOXO-292 | 6 Months - 21 Years | Eli Lilly and Company | |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | NCT03037385 | RET-altered Non... Medullary Thyro... RET-altered Pap... RET-altered Col... RET-altered Sol... Lung Neoplasm Carcinoma, Non-... Thyroid Disease... Thyroid Neoplas... Thyroid Cancer,... Carcinoma, Neur... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Endocrine Syste... Endocrine Gland... Head and Neck N... Adenocarcinoma,... Adenocarcinoma Carcinoma Neoplasms, Glan... Neoplasms by Hi... Neuroendocrine ... Neuroectodermal... Neoplasms, Germ... Neoplasms, Nerv... Colonic Neoplas... Colorectal Neop... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... | pralsetinib (BL... | 18 Years - | Hoffmann-La Roche | |
| Comparison of Micro-dose Human Chorionic Gonadotropin (hCG) With Human Menopausal Gonadotropin (HMG) in Polycystic Ovary Syndrome | NCT00947713 | Endocrine Syste... Gonadal Disorde... | low dose human ... Clomiphen citra... | 18 Years - 30 Years | Royan Institute | |
| Comparison of Micro-dose Human Chorionic Gonadotropin (hCG) With Human Menopausal Gonadotropin (HMG) in Polycystic Ovary Syndrome | NCT00947713 | Endocrine Syste... Gonadal Disorde... | low dose human ... Clomiphen citra... | 18 Years - 30 Years | Royan Institute | |
| Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol) | NCT04373265 | Adrenocortical ... | Relacorilant Pembrolizumab | 18 Years - | Corcept Therapeutics | |
| One Week Comparison Study of PTH and PTHrP Infusions | NCT01333267 | Osteoporosis Hypercalcemia o... Hyperparathyroi... Bone Diseases, ... | Parathyroid Hor... parathyroid hor... PTH (1-34) and ... | 24 Years - 35 Years | University of Pittsburgh | |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | NCT03899792 | Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar... | LOXO-292 | 6 Months - 21 Years | Eli Lilly and Company | |
| Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | NCT01964430 | Pancreatic Neop... Digestive Syste... Neoplasms by Si... Neoplasms Endocrine Gland... Pancreatic Dise... Digestive Syste... Endocrine Syste... Gemcitabine Antimetabolites... | nab-Paclitaxel Gemcitabine | 18 Years - | Celgene | |
| Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors | NCT01215578 | Neuroendocrine ... Pancreatic Neop... Advanced Diseas... Sunitinib | Sutent | 18 Years - | Assistance Publique - Hôpitaux de Paris |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
